Alimentary pharmacology & therapeutics · 2026
Clinical Trial: Multi-Strain Probiotic Improves Bile Acid Profile, Microbiome, and Metabolomic Parameters in Patients With History of Bile Acid Malabsorption-A Randomized, Controlled Trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Damianos John A, Matar Ayah, Carlson Paula, Busciglio Irene, Jencks Kara J, Johnson Stephen, Mars Ruben A, Kashyap Purna C, Harmsen W Scott, Camilleri Michael
Аннотация
BACKGROUND: Bile acid (BA) malabsorption (BAM) is a common cause of chronic diarrhoea and may occur in some patients due to abnormalities of the gut microbiota. Effects of probiotics on faecal secretory BAs, particularly the primary BA, chenodeoxycholic acid, are unclear.
AIM/METHODS: We conducted a randomized, double-blind, placebo-controlled trial of the De Simone formulation 8-strain probiotic in 24 patients previously diagnosed with BAM. Patients were randomized to 3 weeks of the probiotic (900 billion bacteria) or placebo (maltose), both administered three times daily. Symptoms, serum 7αC4, faecal primary BAs, intestinal permeability by 13C-mannitol-lactulose test (0.1 and 1 g of the sugars respectively) over 24 h, faecal short chain fatty acids (SCFA), microbiome, and metabolome were assessed at baseline and post-intervention.
RESULTS: Data from 22 patients were included. Probiotic supplementation was associated with a significant decrease in % faecal primary BAs (chenodeoxycholic acid and cholic acid) with median change from baseline -5.7 [IQR -10.3, 0.9]% compared to 9.8 [IQR 0.2, 20.6]% on placebo (p = 0.012). The faecal microbiome was significantly different in the probiotic group after intervention, driven by probiotic-specific species. There were no significant differences in symptoms, intestinal permeability, or SCFA. However, there was a numerical difference in the changes from baseline in 0-2 h 13C-mannitol excretion -1.9 [-13.9, 4.2] mg for the probiotic and 1.0 (-0.5, 12.7) mg for placebo (p = 0.084).
CONCLUSIONS: The De Simone formulation probiotic induced significant microbiome and metabolome changes in patients with BAM, ultimately leading to a decrease in % faecal primary BAs and possible reduction in intestinal permeability.
CLINICAL TRIALS: gov registration NCT #06609148, January 2, 2025.
AIM/METHODS: We conducted a randomized, double-blind, placebo-controlled trial of the De Simone formulation 8-strain probiotic in 24 patients previously diagnosed with BAM. Patients were randomized to 3 weeks of the probiotic (900 billion bacteria) or placebo (maltose), both administered three times daily. Symptoms, serum 7αC4, faecal primary BAs, intestinal permeability by 13C-mannitol-lactulose test (0.1 and 1 g of the sugars respectively) over 24 h, faecal short chain fatty acids (SCFA), microbiome, and metabolome were assessed at baseline and post-intervention.
RESULTS: Data from 22 patients were included. Probiotic supplementation was associated with a significant decrease in % faecal primary BAs (chenodeoxycholic acid and cholic acid) with median change from baseline -5.7 [IQR -10.3, 0.9]% compared to 9.8 [IQR 0.2, 20.6]% on placebo (p = 0.012). The faecal microbiome was significantly different in the probiotic group after intervention, driven by probiotic-specific species. There were no significant differences in symptoms, intestinal permeability, or SCFA. However, there was a numerical difference in the changes from baseline in 0-2 h 13C-mannitol excretion -1.9 [-13.9, 4.2] mg for the probiotic and 1.0 (-0.5, 12.7) mg for placebo (p = 0.084).
CONCLUSIONS: The De Simone formulation probiotic induced significant microbiome and metabolome changes in patients with BAM, ultimately leading to a decrease in % faecal primary BAs and possible reduction in intestinal permeability.
CLINICAL TRIALS: gov registration NCT #06609148, January 2, 2025.